Childhood hemangiomas and outcome

Year 2022, Volume: 10 Issue: 1, 11 - 15, 15.03.2022

Mehmet Burak Duman Buket Kara , Ahmet Sert , Yavuz Köksal

https://doi.org/10.21765/pprjournal.1022679

Abstract

Childhood hemangiomas and outcome
Objective: The aim of this study is to examine the demographic and clinical characteristics, treatments and outcomes in children diagnosed with hemangioma.
Patients and Methods: Between October 2017 and September 2019, the files of 100 pediatric patients diagnosed with hemangioma were evaluated retrospectively. Demographic and clinical characteristics of the patients, treatment approaches and results were noted.
Findings:
Of the 100 patients included in the study, 66 (66%) were female and 34 (34%) were male. According the age of patients, there were 35, 28, 23, 8, and 6 patients in age groups 0-3 months, 3-6 months, 6-12 months, 12-24 months, and >24 months, respectively. Hemangioma was located in the head and neck region in 68 patients (61%), while extra-head and neck location was detected in 39 (39%) patients. Treatment approaches were oral proporanolol in 71 patients, topical timolol in 21 patients, and oral proporanolol + oral metilprednisolon in 8 patients. Response was obtained in 37 patients (52%) treated with oral propranolol, 7 patients (33%) treated with timolol drops, and three patients (37.5) treated with oral propranolol + oral metilprednisolon. Stable disease was found in 13 (45.1%) of patients receiving oral propranolol, 13 (61.9%) of patients performing topical timolol drop, and four (50%) patients receiving oral propranolol + oral corticosteroid.
Result: Oral propranolol has been observed as an effective and safe treatment method for treatment hemangioma.

Keywords

childhood, hemangioma, propronolol

Çocuk çağı hemanjiyomları ve sonuçları

Abstract

Amaç: Bu çalışmanın amacı hemanjiyom tanısı alan çocuklarda demografik ve klinik özellikleri ile tedavileri ve tedavi sonuçlarının incelenmesidir.
Hastalar ve Yöntemler: Ekim 2017- Eylül 2019 tarihleri arasında hemanjiyom tanısı alan 100 çocuk hastanın dosyası geriye dönük olarak incelendi. Hastaların demografik ve klinik özellikleri, tedavi yaklaşımları ve sonuçları not edildi.
Bulgular: Çalışmaya dâhil edilen 100 hastanın 66’sı (%66) kız, 34’ü (%34) erkekti. Hastaların yaş gruplarına göre, 0-3 ay, 3-6 ay, 6-12 ay, 12-24 ay ve >24 ay yaş gruplarında sırasıyla 35, 28, 23, 8 ve 6 hasta vardı. Atmış bir hastada (%61), hemanjiyom baş-boyun bölgesinde yerleşimli iken, baş-boyun dışı yerleşim 39 (%39) hastada saptandı. Tedavi yaklaşımları 71 hastada oral propranolol, 21 hastada topikal timolol damla ve 8 hastada oral propranolol + oral metilprednisolon idi. Oral propranolol ile tedavi edilen 37 hastada (%52), topikal timolol damla ile tedavi edilen 7 hastada (%33,3) ve oral propranolol + oral metilprednisolon ile tedavi edilen üç hastada (37,5) yanıt alındı. Stabil hastalık, oral propranolol alan hastaların 13'ünde (%45,1), topikal timolol damla uygulanan hastaların 13'ünde (%61,9) ve oral propranolol + oral kortikosteroid alan hastaların dördünde (%50) saptandı.
Sonuç: çocuklarda, hemanjiyom tedavisinde özellikle oral propranolol tedavisinin etkili ve güvenilir bir tedavi yöntemi olduğu gözlemlenmiştir.

Keywords

çocukluk çağı, hemanjiom, propronolol

References

• 1. Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they A systematic review of the medical literature. Pediatr Dermatol 2008;25:168-73.
• 2. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007;150:291-4.
• 3. Colonna V, Resta L, Napoli A, Bonifazi E. Placental hypoxia and neonatal haemangioma: clinical and histological observations. Br J Dermatol 2010;162:208-9.
• 4. Şahin UDG, Aydın F. İnfantil Hemanjiyomlar. 2019;2:1-14.
• 5. Dilek M, Bekdaş M, Göksügür SB, et al. İnfantil hemanjiom ve oral propranolol tedavisi. Şişli Etfal Tıp Bülteni;49:148-51.
• 6. Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and Management of Infantile Hemangioma. Pediatrics 2015;136:e1060-104.
• 7. Püttgen K, Lucky A, Adams D, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics 2016;138:e20160355.
• 8. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.
• 9. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011;128:e259-66.
• 10. Theletsane T, Redfern A, Raynham O, Harris T, Prose NS, Khumalo NP. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol 2009;23:1465-6.
• 11. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015;372:735-46.
• 12. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med. 2010;362:1005-13.
• 13. Kim KH, Choi TH, Choi Y, et al. Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. JAMA Dermatol 2017;153:529-36.
• 14. Caussé S, Aubert H, Saint-Jean M, et al. Propranolol-resistant infantile haemangiomas. Br J Dermatol 2013;169:125-9.
• 15. Wedgeworth E, Glover M, Irvine AD, et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. Br J Dermatol 2016;174:594-601.
• 16. Ahogo CK, Ezzedine K, Prey S, et al. Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. Br J Dermatol 2013;169:1252-6.